Biotricity, Inc. Announces the Sale of Non- Convertible Notes Mature on January 9, 2020
January 15, 2019 at 07:45 pm
Share
On January 9, 2019, pursuant to two purchase agreements Biotricity, Inc. sold to two accredited investors a total of $400,000 in principal amount of notes. The notes are non- convertible, bear an interest rate of 10% per year and mature on January 9, 2020.
Biotricity Inc. is a medical technology company focused on biometric data monitoring and diagnostic solutions. The Company developed its Bioflux technology, comprised of a monitoring device and software components. The Bioflux device is comprised of a wet electrode worn on a belt clip around the waist. The Bioflux ECG reporting software enables doctors and labs to view a patientâs electrocardiogram (ECG) data for monitoring and diagnostic purposes. Its Bioflux platform has a built-in cellular chipset and a real-time embedded operating system, which allows for its technology to be utilized as an Internet of Things (IoT) platform. It has developed several technologies, including Biotres, Bioheart, and Biocare. Biotres is an ECG Holter solution that addresses the limitations of existing solutions in the Holter market. Bioheart is a personal cardiac monitoring solution for consumers. Biocare is a cardiac disease management platform for chronic care management and remote patient monitoring.
BIOTRICITY, INC. 
